Who owns MapLight Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of MPLT from SEC Form 13F filings across 105 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 105 institutions disclosed 26.3M shares of MapLight Therapeutics, Inc. worth $941.0M — about 57.8% of shares outstanding; the largest disclosed holder is NOVO HOLDINGS A/S. Source: SEC Form 13F filings, parsed by EvidInvest.
105
13F holders
$941.0M
value, 2026 filers
57.8%
of shares outstanding (26.3M sh)
36
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of MPLT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | NOVO HOLDINGS A/S | 3.7M | $132.1M | 7.7% | 8.1% | 0.0% |
| 2 | FCPM III SERVICES B.V. | 3.2M | $115.6M | 15.4% | 7.1% | 0.0% |
| 3 | T. Rowe Price Investment Management, Inc. | 2.8M | $99.7M | 0.1% | 6.1% | -0.7% |
| 4 | GOLDMAN SACHS GROUP INC | 1.9M | $69.8M | 0.0% | 4.3% | -2.3% |
| 5 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.4M | $51.0M | 0.0% | 3.1% | +1162.5% |
| 6 | BlackRock, Inc. | 1.0M | $36.7M | 0.0% | 2.3% | -23.5% |
| 7 | Nan Fung Group Holdings Ltd | 971,253 | $34.8M | 26.5% | 2.1% | 0.0% |
| 8 | 5AM Venture Management, LLC | 950,011 | $34.0M | 11.8% | 2.1% | 0.0% |
| 9 | Sanofi | 912,041 | $32.7M | 6.1% | 2% | 0.0% |
| 10 | STATE STREET CORP | 852,150 | $30.5M | 0.0% | 1.9% | +151.3% |
| 11 | FMR LLC | 823,556 | $29.5M | 0.0% | 1.8% | +302.7% |
| 12 | VANGUARD CAPITAL MANAGEMENT LLC | 784,150 | $28.1M | 0.0% | 1.7% | +8.9% |
| 13 | Blue Owl Capital Holdings LP | 729,929 | $26.2M | 3.9% | 1.6% | -27.4% |
| 14 | Paradigm Biocapital Advisors LPNEW | 685,852 | $24.6M | 0.5% | 1.5% | new |
| 15 | Pivotal bioVenture Partners Investment Advisor LLC | 611,446 | $21.9M | 7.1% | 1.3% | 0.0% |
| 16 | Velan Capital Investment Management LP | 492,893 | $17.7M | 10.8% | 1.1% | 0.0% |
| 17 | Siren, L.L.C. | 450,000 | $16.1M | 0.3% | 1% | 0.0% |
| 18 | Capital World InvestorsNEW | 415,730 | $14.9M | 0.0% | 0.9% | new |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 402,051 | $14.4M | 0.0% | 0.9% | -16.4% |
| 20 | BAKER BROS. ADVISORS LP | 364,705 | $13.1M | 0.1% | 0.8% | 0.0% |
| 21 | DAFNA Capital Management LLC | 171,006 | $6.1M | 1.2% | 0.4% | 0.0% |
| 22 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 170,862 | $6.1M | 0.0% | 0.4% | -36.2% |
| 23 | Freestone Grove Partners LP | 168,912 | $6.1M | 0.0% | 0.4% | -46.2% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 136,818 | $4.9M | 0.0% | 0.3% | -15.1% |
| 25 | MILLENNIUM MANAGEMENT LLCNEW | 128,841 | $4.6M | 0.0% | 0.3% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.